37.86

1.53% 0.57

Harmony Biosciences Holdings Inc (HRMY)

Overview News Price History Option Chain Financials Why HRMY Down? Discussions Forecast

Harmony Biosciences Holdings Inc stock is traded at $37.86, with a volume of 491.91K. It is up +1.53% in the last 24 hours and up +3.19% over the past month. Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Previous Close:

$37.29

Open:

$37.45

24h Volume:

491.91K

Relative Volume:

0.82

Market Cap:

$2.18B

Revenue:

$681.88M

Net Income/Loss:

$122.63M

P/E Ratio:

17.94

EPS:

2.11

Net Cash Flow:

$220.18M

1W Performance:

+2.69%

1M Performance:

+3.19%

6M Performance:

+9.55%

1Y Performance:

+5.14%

1-Day Range:

$37.28

$38.05

1-Week Range:

$36.08

$38.05

52-Week Range:

$26.47

$41.61

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Name

Harmony Biosciences Holdings Inc

Sector

Healthcare (1157)

Industry

Biotechnology (645)

Phone

(484) 539-9800

Address

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Employee

268

Twitter

Next Earnings Date

2024-10-29

Latest SEC Filings

HRMY's Discussions on Twitter

Compare HRMY with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HRMY Harmony Biosciences Holdings Inc	37.86	2.09B	681.88M	122.63M	220.18M	2.11
VRTX Vertex Pharmaceuticals Inc	395.12	99.96B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	589.48	60.83B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	454.38	59.89B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	660.00	40.47B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	313.67	37.96B	3.81B	-644.79M	-669.77M	-6.24

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-21-25	Initiated	Truist	Buy
Jul-10-25	Resumed	Goldman	Neutral
Jun-02-25	Resumed	Oppenheimer	Outperform
Feb-11-25	Initiated	Deutsche Bank	Buy
Dec-17-24	Initiated	H.C. Wainwright	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Sep-10-24	Initiated	UBS	Buy
Jun-21-24	Initiated	Citigroup	Buy
Jan-02-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-25-23	Downgrade	Goldman	Neutral → Sell
Sep-07-23	Initiated	Berenberg	Buy
Apr-20-23	Initiated	BofA Securities	Neutral
Oct-14-22	Upgrade	Janney	Neutral → Buy
Oct-14-22	Upgrade	Jefferies	Hold → Buy
Aug-03-22	Downgrade	Jefferies	Buy → Hold
Jul-13-22	Downgrade	Goldman	Buy → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-14-22	Initiated	Cantor Fitzgerald	Overweight
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-04-21	Initiated	Raymond James	Outperform
Sep-23-21	Initiated	Needham	Buy
Mar-29-21	Upgrade	Goldman	Neutral → Buy
Sep-14-20	Initiated	Goldman	Neutral
Sep-14-20	Initiated	Jefferies	Buy
Sep-14-20	Initiated	Piper Sandler	Overweight

View All

Harmony Biosciences Holdings Inc Stock (HRMY) Latest News

Aug 20, 2025

Harmony Biosciences: Reiterating Buy Ahead Of Data Catalyst For Cannabinoid Drug (HRMY) - Seeking Alpha

Aug 20, 2025

Aug 18, 2025

Harmony Biosciences Delivers Strong Q2 Growth, Advances Late-Stage Pipeline - MSN

Aug 18, 2025

Published on: 2025-08-18 22:43:20 - sundaytimes.kr

Aug 18, 2025

Aug 15, 2025

Harmony Biosciences Reaches Settlement with Lupin Over WAKIX® Patent Litigation - MSN

Aug 15, 2025

Aug 14, 2025

H.C. Wainwright Remains a Buy on Harmony Biosciences Holdings (HRMY) - MSN

Aug 14, 2025

Trendline Breach Raises Concern for Harmony Biosciences Holdings Inc. InvestorsDay Trade & Weekly Sector Rotation Insights - beatles.ru

Aug 14, 2025

Aug 13, 2025

Mizuho Lifts Harmony Biosciences Target to $50, Citing Confidence in Fragile X Trial - Insider Monkey

Aug 13, 2025

Harmony Biosciences Holdings Inc. Stock Poised for Technical ComebackJuly 2025 Patterns & Verified Momentum Stock Ideas - sundaytimes.kr

Aug 13, 2025

Aug 12, 2025

10 Best Cheap Growth Stocks to Buy According to Analysts - Insider Monkey

Aug 12, 2025

Aug 11, 2025

Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $50 - 富途牛牛

Aug 11, 2025

Mizuho raises Harmony Biosciences stock price target to $50 on increased confidence - Investing.com Canada

Aug 11, 2025